SCM
RPTP

Stonepine Capital Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Stonepine Capital Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,000
Closed -$92K – 30
2016
Q1 		$92K Buy
+20,000
New +$80.4K 0.11% 15

Other funds holding RPTP

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stonepine Capital Management's RPTP Position: Q2 2016 in Review

Stonepine Capital Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q2 2016, closing a stake of 20,000 shares — an estimated $92K sold.

Stonepine Capital Management first reported a position in RPTP in Q1 2016 and held it in 1 quarter. The position peaked at $92K in Q1 2016. 93 funds tracked by Wall St. Rank hold RPTP as of Q2 2016.

  • Stonepine Capital Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Stonepine Capital Management sold 20,000 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q2 2016, an estimated $92K.
  • Stonepine Capital Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q1 2016 and held it in 1 quarter.
  • Stonepine Capital Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $92K in Q1 2016.
  • 93 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q2 2016.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.